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Abstract
The study’s objective was to assess the cost-effectiveness of preoperative transfusion compared with no
preoperative transfusion in patients with sickle cell disease undergoing low- or medium-risk surgery. Seventy
patients with sickle cell disease (HbSS/Sß0thal genotypes) undergoing elective surgery participated in a
multicentre randomised trial, Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS). Here, a
cost-effectiveness analysis based on evidence from that trial is presented. A decision-analytic model is used
to incorporate long-term consequences of transfusions and acute chest syndrome. Costs and health
benefits, expressed as quality-adjusted life years (QALYs), are reported from the ‘within-trial’ analysis and for
the decision-analytic model. The probability of cost-effectiveness for each form of management is calculated
taking into account the small sample size and other sources of uncertainty. In the range of scenarios
considered in the analysis, preoperative transfusion was more effective, with the mean improvement in
QALYs ranging from 0.018 to 0.206 per patient, and also less costly in all but one scenario, with the mean
cost difference ranging from £813 to £26. All scenarios suggested preoperative transfusion had a probability
of cost-effectiveness >0.79 at a cost-effectiveness threshold of £20 000 per QALY.
Key words cost; quality-adjusted life years; cost-effectiveness; Transfusion Alternatives Preoperatively in Sickle Cell Disease trial;
transfusion; sickle cell disease
Correspondence Eldon Spackman, Centre for Health Economics, University of York, Alcuin ’A’, Hesslington, York YO10 5DD,
Tel:+1904321401; Fax: +1904321402; e-mail: eldon.spackman@york.ac.uk
Accepted for publication 3 November 2013 doi:10.1111/ejh.12232
Patients with sickle cell disease (SCD) often require sur-
gery, and peri-operative complications are common (1, 2).
Preoperative blood transfusion has been associated with
decreased peri-operative complications, but is also associ-
ated with increased acute transfusion reactions, alloimmuni-
sation and delayed haemolytic transfusion reactions.
Preoperative transfusions are usually given to patients
undergoing high-risk surgery, but there is no consensus
about the role of transfusion in patients undergoing low- or
medium-risk surgery.
A multicentre randomised trial, Transfusion Alternatives Pre-
operatively in Sickle Cell Disease (TAPS), was undertaken
to assess whether routine preoperative transfusion increases
or decreases the risk of peri-operative complications in
patients undergoing low- or medium-risk surgery (3). The
primary outcome was the proportion of patients with clini-
cally important complications between randomisation and up
to and including 30 d postsurgery. Complications were clas-
siﬁed as related to SCD, infection, surgery or transfusion.
Complications, which were life-threatening or resulted in
death, permanent or severe disability, or other important
medical outcomes, were also reported as serious adverse
events (SAEs). A signiﬁcant imbalance in SAEs resulted in
early trial closure in March 2011.
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This trial showed a statistically signiﬁcant increase in com-
plications, predominantly acute chest syndrome (ACS), in un-
transfused SCD patients having low- or medium-risk surgery.
Although limited by early closure and a small number of par-
ticipants, this evidence suggests that patients with SCD have
better outcomes if they receive a blood transfusion before sur-
gery. However, the published trial results do not weigh the
positive short-term outcomes of transfusion vs. the risk of
transfusion complications, nor do they consider the costs asso-
ciated with the alternative forms of management.
Therefore, a cost-effectiveness analysis was undertaken to
compare preoperative blood transfusion with no transfusion
for patients with SCD (HbSS/Sß0thal genotypes) undergoing
low- or medium-risk elective surgery using data from the
TAPS trial. The analysis incorporated the short-term
costs and beneﬁts, and long-term implications of transfusion
complications.
Methods
Overview
The cost-effectiveness analysis was undertaken from the per-
spective of the UK National Health Service (NHS), with out-
comes expressed as quality-adjusted life years (QALYs).
Two linked analyses were undertaken. Firstly, a ‘within-trial’
analysis was undertaken which used trial resource-use and
outcome data over a period of 1-year follow-up. Secondly, a
decision-analytic model was used to extrapolate the esti-
mated costs and outcomes over the longer term. In particu-
lar, the model was used to capture the prognostic
implications of complications observed in the trial.
Trial design
Full details of TAPS are available elsewhere (3). Brieﬂy, it
was a multicentre, pragmatic, randomised controlled trial,
with a group sequential superiority design. It was carried out
between November 2007 and March 2011 at 22 sites in Eng-
land, the Netherlands, Ireland and Canada, with appropriate
ethical approval and written patient/parental consent. An
interim analysis was scheduled after every 40 patients. Sec-
ondary outcomes included health-related quality of life [using
the EQ-5D instrument (4)] and resource use: number of days
in hospital; units of blood transfused; the use of heparin, anti-
biotics or pain medication; and other peri-operative treat-
ments such as oxygen, spirometry and blood warming.
Cost analysis
Costs were assessed from the perspective of the UK NHS.
In the within-trial analysis, mean costs per treatment arm
were calculated by applying unit costs taken from routine
NHS sources and the published literature, to resource-use
data from the trial (Table 1). In the decision-analytic model,
costs were extrapolated to the lifetime of the patient by sum-
ming the within-trial costs and the expected costs of transfu-
sion complications. All costs are reported in 2011 UK
sterling adjusting for inﬂation using the Health and Commu-
nity Health Services price index (PSSRU 2011).
Health outcomes
In TAPs, EQ-5D data were collected at baseline and at 30-
day postsurgery follow-up. At the time of trial set-up in
2005, no reliable tool similar to the EQ-5D was available
for patients younger than 12 yr of age. Therefore, EQ-5D
data were only collected for those aged 12 yr and older at
entry. For the within-trial analysis, QALYs were calculated
using area under the curve methods (5) based on EQ-5D
responses at baseline and at 30 d follow-up. In the base
case, it was assumed that patients’ follow-up responses were
sustained until the end of the year. Sensitivity analysis was
used to assess the effect of assuming that all patients
Table 1 Unit costs
Resources
Costs (£ 2011)
Source
Base
case Low High
Cost per unit of
blood
136.50 124.52 329.94 (8, 15, 16)
Heparin (per day) 3.56 2.82 4.04 BNF (tinzaparin
sodium, 4500
units)
Antibiotics
(per day)
7.83 4.70 10.96 BNF (ampicillin,
500 mg injection)
Pain medication
(per day)
14.64 8.78 20.50 BNF (codeine
phosphate, 60 mg,
every 4 h)
Active warming
(per procedure)
20.15 12.09 28.20 Guys and St
Thomas NHS
foundation trust
Blood warming
(per procedure)
11.85 7.11 16.59 Guys and St
Thomas NHS
foundation trust
Incentive
spirometry
(per procedure)
90.00 54.00 126.00 Clinical opinion
CPAP
(per procedure)
2.00 1.20 2.80 Cost of mask and
tubing
Supplemental O2
(per procedure)
2.00 1.20 2.80 Cost of mask and
tubing
Chest X-ray
(per procedure)
88.92 53.35 124.49 (17, 18)
Cost of day
in ICU
1234.06 635.08 1833.04 (8, 17)
Cost of day
in HDU
873.22 757.12 989.32 (15, 17)
Additional
bed day
246.33 186.62 277.07 (8, 15, 17)
CPAP, central positive airway pressure.
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returned to normal health by the end of the year if their fol-
low-up EQ-5D score was below that of normal health. The
decision model considered the health consequences of poten-
tial transfusion complications.
‘Within-trial’ analysis
Seemingly, unrelated regression was used to take into
account the correlation between estimates of mean costs and
QALYs (6), and controlling for baseline EQ-5D (7). Further
analyses also controlled for age, sex and surgery risk. A
complete case analysis was undertaken on all trial patients
without missing data. This analysis does not include patients
<12 yr as no EQ-5D were collected. For subsequent analy-
ses, QALYs were estimated for patients less than age 12 yr
using multiple imputation regression analysis to control for
age, sex, surgery risk, surgery type as well as surgery out-
comes and indicators for presurgery health.
Decision model analysis
Transfusion complications are rare, but the consequences can
be costly (8). TAPs is likely to have been too small a trial
with too short a follow-up to provide reliable estimates of the
long-term implications of these complications. Therefore,
additional costs of transfusion complications are calculated
using published lifetime cost estimates, which are estimated
to be more than £180 000 in the case of HIV (Table 2).
Taking into account the low probability of occurrence of
transfusion complications, the mean additional cost of all
transfusion complications is estimated to be £1.69 per transfu-
sion.
To understand the potential long-term health effects of
transfusion complications, the median survival of patients
with SCD was assumed to be 55.8 yr, calculated as a
weighted average according to the male/female split of
TAPS (9). The average age of a patient in TAPS was
17.3 yr. The calculated life expectancy used in the model
was 38.5 yr.
The additional loss of QALYs for those living with trans-
fusion complications was calculated by assuming a 0.05
health-related quality of life (HRQoL) decrement (8) for
38.5 yr for hepatitis B and HIV and for 1 month for a hae-
molytic transfusion reaction, post-transfusion purpura, vCJD,
hepatitis A or malaria. The probabilities of death from trans-
fusion complications (Table 3) were those used in previous
analyses (8). It was assumed that death resulted in the loss
of 0.93 QALYs per year for 38.5 yr. No QALY decrements
were calculated for hepatitis C or HTLV as the probability
of these events was considered to be vanishingly small (8).
On this basis, the health outcome was estimated to be a loss
of 0.0016 QALYs per transfusion.
In the TAPS trial, no patients died from ACS or other
causes (3). However, previous trials have shown an
increased risk of death from ACS (10). The base-case analy-
sis is conservative as it excludes the long-term consequences
of ACS, the most common adverse event, and was lower in
patients with preoperative transfusions. We estimated that
0.64 QALYs are lost per occurrence of acute chest syn-
drome (probability of death 0.018 9 length of life lost
38.5 9 health-related quality of life lost 0.93), which was
used in a further scenario analysis.
Economic analysis
The economic statistic used is the incremental cost-effective-
ness ratio (ICER). This is calculated as the difference in
costs divided by the difference in effect, in this case
QALYs.
Table 2 Long-term costs of blood transfusions
Transfusion complications
Probability
of event1
Cost
(£ 2011)
Source
of costs
Transfusion-related graft
vs. host disease
0.000002 11 057 (8)
Incorrect blood
component transfused
0.000244 2221 (8)
Haemolytic transfusion
reaction
0.000081 8547 (8)
Post-transfusion purpura 0.000008 1796 (8)
Transfusion-related acute
lung injury
0.000025 3486 (8)
Fatal air embolism 0.00003 3082 (8)
Variant Creutzfeldt–Jakob
disease
0.0000012 179 730 (8)
Human immunodeficiency
virus
0.0000001 181 825 (8)
Human T-cell lymphotropic
virus
– 178 688 (8)
Malaria 0.0000012 1419 (8)
Hepatitis A 0.0000012 3030 (8)
Hepatitis B 0.0000001 34 119 Assumption
Hepatitis C – 34 119 (19)
Total expected additional
cost
1.69 Calculation
1The probability of an event after having a transfusion (8).
Table 3 Probability of death due to complications from blood
transfusions
Complications
Probability
of death Source
Transfusion-related graft vs. host disease 1 (8)
Incorrect blood component 0.012 (8)
Haemolytic transfusion reaction acute 0.043 (8)
Haemolytic transfusion reaction delayed 0.038 (8)
Post-transfusion purpura 0.046 (8)
Transfusion-related acute lung injury 0.237 (8)
Fatal air embolism 1 (8)
Acute chest syndrome 0.018 (10)
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ICER ¼ CostA  CostB
QALYsA  QALYsB
Treatment A is said to be dominated by Treatment B if
Treatment A is less effective but more costly. Treatment A
is said to be cost saving if it is more effective and less
costly. When CostA > CostB and QALYsA > QALYsB, this
ratio represents the additional cost for each additional QALY
produced by Treatment A. To determine whether a treatment
which is more effective but also more costly is cost-effec-
tive, we compare it to a threshold. The threshold represents
the opportunity costs of the National Health Service (NHS)
or the health expected to be forgone elsewhere as other
NHS activities are displaced. The National Institute of
Health and Care Excellence (NICE) decision threshold is
currently £20 000–£30 000 per QALY gained, although
recent research suggests the threshold might actually be
lower (11). This suggests that NICE is likely to accept new
treatments with an ICER <£20 000 per QALY. This is
because the QALYs produced by the new treatment will be
less expensive than the QALYs displaced elsewhere in the
NHS by the additional cost of the new treatment.
Uncertainty in the parameters estimated in the trial was
combined with uncertainty in parameters from the literature
using probabilistic sensitivity analysis (PSA) (12). Inputs
were deﬁned using appropriate probability distributions to
reﬂect their full uncertainty, taking into account known cor-
relations between parameters. Monte Carlo simulation was
undertaken to estimate the combined uncertainty of the
parameters within the model. The probability of each form
of management being more cost-effective was calculated
from 1000 simulations.
The likelihood of making a wrong decision (one minus
the probability of being cost-effective) was combined with
the potential health and cost consequences of a wrong deci-
sion to calculate the expected value of perfect information
(EVPI), the value of avoiding all consequences of a wrong
decision, equivalent to the value of being able to resolve all
decision uncertainty and indicating the maximum value a
health system attaches to further research. A value of EVPI
higher than the anticipated cost of further research is a nec-
essary condition for further research to be good value. To
estimate the EVPI, it was necessary to estimate the number
of SCD patients likely to undergo surgery and who would
be eligible for this treatment. In a survey of 31 of the 41
hospitals that were known to treat patients with SCD, 136
procedures were reported between May 2002 and May 2003
(1). We assumed 175 procedures would occur each year
assuming the number of SCD patients has increased in the
UK since 2002 and that the survey was a representative
sample of UK hospitals. We assumed that if preoperative
transfusion is taken up as routine practice over the next
10 yr, approximately 1750 SCD patients could be treated
with preoperative transfusions.
Results
‘Within-trial’ analysis
Of the 70 patients randomized in TAPS, 67 were included
in the clinical analysis. The three patients excluded were
randomized in error: one with high-risk surgery and two for
having had a transfusion within 3 months of scheduled
surgery not declared at enrolment.
Complete resource-use data were collected for 64 patients,
one patient had missing information on whether they had
received blood warming, one patient had missing informa-
tion on whether they had received peri-operative heparin and
one patient withdrew, and no resource-use data were
collected.
Resource-use estimates were similar across treatment arms.
Patients with no preoperative transfusion received a mean of
0.85 fewer units of blood per patient and were more likely
to use incentive spirometry (Table 4). Costs were higher in
the no preoperative transfusion arm, including scenarios
based on low and high estimates of unit costs (Table 5).
Of the 36 patients 12 yr or older, 35 completed the base-
line EQ-5D, 29 completed the follow-up EQ-5D and 14
from each arm completed both. Patients who had no preop-
erative transfusion had higher baseline and follow-up HRQL
and higher unadjusted QALYs (Table 6). Adjusting for base-
line HRQL, patients receiving preoperative transfusion had
0.018 higher mean QALYs and £735 lower mean costs
(Table 7). There was a 0.79 probability of preoperative
transfusions being cost-effective at a cost-effectiveness
threshold of £20 000 per QALY.
Table 4 Within-trial analysis: resource-use estimates by treatment
Treatment
No preoperative
transfusion
Preoperative
transfusion
% of patients receiving
Heparin 9.4 15.1
Antibiotic 97.0 90.9
Patient warmed 84.8 84.8
Blood warmed 9.4 6.0
Incentive spriometry 36.4 6.0
CPAP 3.0 3.0
Supplemental O2 78.8 81.8
Chest x-ray1 12.1 2.9
Mean (SD)
Length of stay days 4.7 (3.7) 4.1 (3.6)
ICU days 0.3 (1.3) 0.0 (0.0)
HDU days 0.1 (0.4) 0.1 (0.3)
Units of blood2 1.2 (2.3) 2.1 (1.5)
1Collected from complication reports, associated with ACS.
2Includes all blood transfusions reported in the trial.
252 © 2013 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.
CEA of preoperative transfusion Spackman et al.
‘Within-trial’ analysis: multiple imputation
The use of methods to impute HRQoL for patients aged under
12 yr resulted in an estimated 0.057 mean additional QALYs
per patient and a mean cost reduction of £813 for preopera-
tively transfused patients (Table 7). In the subgroup of
patients younger than 12 yr, mean QALYs were also higher
by 0.157, but mean costs were £26 higher for preoperatively
transfused patients giving an incremental cost-effectiveness
ratio of £163 per additional QALY. Following imputation for
all missing data in the study, preoperative transfusions
improved mean QALYs by 0.018 per patient and lowered
mean costs by £446. The probability of being cost-effective at
a cost-effectiveness threshold of £20 000 per QALY was 0.92.
In a further analysis age, sex and surgery risks were
included as covariates. Preoperative transfusion had higher
QALYs and was less costly, with 0.090 higher mean
QALYs, and a mean cost of £717 lower.
Table 5 Within-trial analysis: estimated treatment costs
Treatment
No preoperative transfusion Preoperative transfusion
Mean (SD) per patient
Type of cost Base case Low cost High cost Base case Low cost High cost
Blood £157 (£307) £143 (£280) £380 (£743) £273 (£211) £249 (£193) £660 (£511)
Other £1766 (£2515) £1233 (£1548) £2200 (£3539) £1405 (£1062) £1115 (£833) £1965 (£1414)
Total £1924 (£2762) £1377 (£1773) £2583 (£4148) £1447 (£1050) £1148 (£823) £2023 (£1394)
Table 6 Complete case unadjusted health-related quality of life and QALYs
Trial results
No preoperative transfusion Preoperative transfusion
N Mean SD Min Max N Mean SD Min Max
Baseline EQ-5D 17 0.793 0.298 0.055 1 18 0.76 0.236 0.016 1
Follow-up EQ-5D 15 0.864 0.190 0.516 1 14 0.854 0.166 0.516 1
QALYs1 14 0.857 0.186 0.520 1 14 0.849 0.164 0.525 1
1Not adjusted for baseline EQ-5D.
Table 7 Cost-effectiveness results for multiple scenarios
Scenario Intervention Costs (SD) QALYs (SD) ICER1
Probability of
cost-effectiveness
Complete case in trial analysis No transfusion £2442 (615) 0.696 (0.037) Preoperative transfusion is less
costly and more effective
0.79
Transfusion £1706 (615) 0.714 (0.040)
Difference £735 (869) 0.018 (0.048)
Patients ≥12 yr old imputed trial analysis No transfusion £2685 (142) 0.628 (0.197) Preoperative transfusion is less
costly and more effective
0.88
Transfusion £1872 (135) 0.686 (0.110)
Difference £813 (196) 0.057 (0.134)
Patients <12 yr old, imputed trial analysis No transfusion £961 (592) 0.569 (0.048) £163 per additional QALY 0.86
Transfusion £986 (593) 0.727 (0.049)
Difference £26 (838) 0.157 (0.061)
All patients imputed trial analysis No transfusion £1901 (348) 0.660 (0.066) Preoperative transfusion is less
costly and more effective
0.92
Transfusion £1455 (343) 0.743 (0.052)
Difference £446 (489) 0.083 (0.058)
All patients, imputed trial analysis assuming
all patients return to normal health
No transfusion £1901 (348) 0.795 (0.026) Preoperative transfusion is less
costly and more effective
0.95
Transfusion £1455 (343) 0.842 (0.024)
Difference £446 (489) 0.048 (0.029)
Extrapolation of scenario 5 to long term
(includes transfusion complications)
No transfusion £1897 (359) 0.664 (0.081) Preoperative transfusion is less
costly and more effective
0.89
Transfusion £1481 (347) 0.744 (0.092)
Difference £416 (514) 0.080 (0.066)
Scenario 6 additionally including mortality
of ACS
No transfusion £1901 (343) 0.498 (0.105) Preoperative transfusion is less
costly and more effective
0.99
Transfusion £1450 (335) 0.704 (0.094)
Difference £451 (484) 0.206 (0.091)
1Incremental cost-effectiveness ratio.
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Decision model
When the costs and health effects of transfusion complica-
tions are included using the decision model, the estimated
mean difference was 0.080 additional QALYs and £416
lower mean costs for patients undergoing preoperative trans-
fusion, with a 0.91 probability of the procedure being cost-
effective at a cost-effective threshold of £20 000 per QALY.
The EVPI was estimated to be £138 511 (Table 7).
In a further scenario analysis, we included the QALY dec-
rement due to death from acute chest syndrome. The proba-
bility of preoperative transfusion being cost-effective
increased to 0.99 and the value of information decreased to
£12 848.
Discussion
This analysis suggests preoperative transfusion is cost-effec-
tive and may be cost saving. Multiple scenario and sensitiv-
ity analyses were undertaken all suggesting preoperative
transfusion has a high probability of being cost-effective at
the standard cost-effectiveness threshold used by the
National Institute of Health and Care Excellence (13).
The trial results are uncertain given the limited number of
patients, the lack of EQ-5D data for half the trial participants
and the short follow-up time. A decision model was created
to explore the uncertainties of the trial data. Missing data
were imputed, long-term health effects, and costs due to
transfusion were modelled, and the uncertainties around the
model parameter estimates were considered in a probabilistic
sensitivity analysis.
EQ-5D data were only collected for those 12 yr and older,
as no valid instrument was available for patients under
12 yr. Thirty-one trial participants did not complete the
EQ-5D because of their age. A complete case analysis will
give us an estimate of the cost-effectiveness of treatment in
patients 12 yr and older. However, imputation methods
taking advantage of information available in the trial on
events, and patient characteristics can be used to estimate
EQ-5D scores for patients <12 yr old. For this method to be
reliable, we must assume that the difference in patients that
completed the EQ-5D and those that did not can be
explained given the other variables that have been collected
in the trial, such as age, surgery risk, surgery type hospital
days and comorbidities such as asthma or renal impairment.
This analysis assumes those <12 yr old would have
answered the EQ-5D in the same way as the respondents did
and does not take into account that children’s experiences
and outcomes might be different. Results were presented for
each age subgroup to see the incremental effect of these
assumptions.
For imputation, we use truncated regressions to limit the
range of possible EQ-5D scores between the instruments
range and to allow the scores of those <12 yr to be different
than the scores of those >12 yr. Imputation was undertaken
in a step-wise manner to assess its effect on the adoption
decision. First, data were imputed to the ≥12-year-old popu-
lation (scenario 2) and then to the <12-year-old population
(scenario 3). Scenario 4 combined the two age groups. All
in trial scenarios resulted in preoperative transfusion being
cost-effective.
The population from scenario 4 was then used to extrapo-
late beyond the trial timeframe using decision-model analy-
sis. Including transfusion costs and long-term consequences
resulted in higher costs and lower QALYs for the preopera-
tive transfusion group compared with scenarios 1–4, but
compared with the no preoperative transfusion group costs
remained lower and QALYs higher (scenario 6).
A 1988 through to 1993 multicentre randomised controlled
trial compared the complication rates in sickle cell patients
receiving aggressive (haemoglobin S level to <30%) or con-
servative (increase haemoglobin to 10 g per decilitre) preoper-
ative transfusions (14). The authors concluded that a
conservative transfusion regimen was as effective as an
aggressive regimen in preventing peri-operative complications
in patients will sickle cell anaemia, and the conservative
approach resulted in only half as many transfusion-associ-
ated complications. No comparison was made to a no trans-
fusion arm, and patients undergoing severe surgeries were
also included. They found that 10% of patients in each arm
had ACS with two of the 303 patients in the aggressive regi-
men dying from ACS (14).
In the TAPS study, the increased occurrence of ACS in
the arm that did not receive preoperative transfusion may
have longer term health effects and costs than were captured
in the study. In a scenario analysis, we included the loss of
QALYs associated with this increased mortality (scenario 7).
These results strengthen the conclusion and the addition of
long-term costs of ACS make transfusion more cost saving.
However, the mortality estimates are from a 20-year-old
study (10) and should be considered cautiously as it is possi-
ble that, with recent improvements in patient treatment, cur-
rent mortality from ACS is lower. If the mortality estimates
of ACS are lower than those used in the model, then it
would be expected that the actual beneﬁts of preoperative
transfusion to be somewhere between scenarios 6 and 7.
All analyses suggested there was low decision uncertainty
taking into account the small trial population. The probabi-
listic sensitivity analysis took into account the uncertainty
around the QALYs and costs estimated in the trial and the
correlation between the two as well as the uncertainty of the
costs and health outcomes of the potential transfusion com-
plications used in the extrapolation analyses. This combined
uncertainty gives us a probability of the cost-effectiveness of
preoperative transfusions, which in all scenarios is >79%.
The EVPI was never higher than £138 511. This suggests
that the value to the NHS of resolving all of the uncertainty
considered in the economic model is relatively low. This
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supports the decision to stop the trial early as further infor-
mation was unlikely to change the conclusions of this analy-
sis. Due to small numbers and particularly the small number
of patients recruited overseas, it was not possible to take into
account the differential cost-effectiveness based on country
or risk of surgery as planned in the protocol.
The results of this cost-effectiveness analysis support the
use of preoperative transfusion for treating patients with
sickle cell anaemia undergoing low- and moderate-risk
surgery.
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